Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL BRONCHIOLITIS DRUGS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL BRONCHIOLITIS DRUGS MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY BASED METHOD
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL BRONCHIOLITIS DRUGS MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER'S 5 FORCES
4.2 PESTEL ANALYSIS
5 EPIDEMIOLOGY
5.1 INCEDENCE OF BRONCHIOLITIS, BY COUNTRY
5.2 TREATMENT RATE
5.3 MORTALITY RATE
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
5.5 PATEINT TREATMENT SUCCESS RATES
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.4 PATIENT FLOW DIAGRAM
6.5 KEY PRICING STRATEGIES
6.6 KEY PATIENT ENROLLMENT STRATEGIES
6.7 INTERVIEWS WITH NEUROLOGIST
6.8 INTERVIEWS WITH ONCOLOGIST
6.9 INTERVIEWS WITH GENETICS SPECIALIST
6.1 OTHER KOL SNAPSHOTS
7 REGULATORY SCENARIO
7.1 FDA APPROVALS
7.2 EMA APPROVALS
8 MERGERS AND ACQUISITION
8.1 LICENSING
8.2 COMMERCIALIZATION AGREEMENTS
9 PIPELINE ANALYSIS
9.1 CLINICAL TRIALS AND PHASE ANALYSIS
9.2 DRUG THERAPY PIPELINE
9.3 PHASE III CANDIDATES
9.3.1 LIPOSOMAL CYCLOSPORINE A
9.3.2 OTHERS
9.4 PHASE II CANDIDATES
9.5 PHASE I CANDIDATES
9.5.1 PRIFENIDONE
9.5.2 VACCINES
9.5.2.1. IVX-121
9.5.2.2. IVX-AI2
9.6 OTHERS (PRE-CLINICAL AND RESEARCH)
10 MARKET OVERVIEW
10.1 DRIVERS
10.2 RESTRAINS
10.3 OPPURTUNITY
10.4 CHALLENGES
11 GLOBAL BRONCHIOLITIS DRUGS MARKET, BY TYPE
12 (NOTE- THERE IS NO TREATMENT THAT CAN GET RID OF BRONCHIOLITIS, SO TREATMENT IS AIMED AT RELIEVING SYMPTOMS UNTIL THE INFECTION RESOLVES)
12.1 OVERVIEW
12.2 CORTECOSTEROIDS
12.2.1 DEXAMETHASONE
12.2.1.1. MARKET VALUE (USD MN)
12.2.1.2. MARKET VOLUME (SU)
12.2.1.3. AVERAGE SELLING PRICE (USD)
12.2.2 PREDNISOLONE
12.2.2.1. MARKET VALUE (USD MN)
12.2.2.2. MARKET VOLUME (SU)
12.2.2.3. AVERAGE SELLING PRICE (USD)
12.2.3 BUDESONIDE
12.2.3.1. MARKET VALUE (USD MN)
12.2.3.2. MARKET VOLUME (SU)
12.2.3.3. AVERAGE SELLING PRICE (USD)
12.2.4 OTHERS
12.3 RIBAVIRIN (VIRAZOLE)
12.3.1 MARKET VALUE (USD MN)
12.3.2 MARKET VOLUME (SU)
12.3.3 AVERAGE SELLING PRICE (USD)
12.4 NEBULIZED FUROSEMIDE
12.4.1 MARKET VALUE (USD MN)
12.4.2 MARKET VOLUME (SU)
12.4.3 AVERAGE SELLING PRICE (USD)
12.5 INTERFERON ALFA-2A (ROFERON-A)
12.5.1 MARKET VALUE (USD MN)
12.5.2 MARKET VOLUME (SU)
12.5.3 AVERAGE SELLING PRICE (USD)
12.6 NEBULIZED EPHINEPHRINE
12.6.1 MARKET VALUE (USD MN)
12.6.2 MARKET VOLUME (SU)
12.6.3 AVERAGE SELLING PRICE (USD)
12.7 BRONCHODILATORS
12.7.1 IPRATROPIUM BROMIDE
12.7.1.1. MARKET VALUE (USD MN)
12.7.1.2. MARKET VOLUME (SU)
12.7.1.3. AVERAGE SELLING PRICE (USD)
12.7.2 NEBULIZED ABUTEROL
12.7.2.1. MARKET VALUE (USD MN)
12.7.2.2. MARKET VOLUME (SU)
12.7.2.3. AVERAGE SELLING PRICE (USD)
12.7.3 OTHERS
13 GLOBAL BRONCHIOLITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 INHALATION
13.3 ORAL
13.4 PARENTERAL
13.5 OTHERS
14 GLOBAL BRONCHIOLITIS DRUGS MARKET, BY POPULATION TYPE
14.1 OVERVIEW
14.2 GERIATRIC
14.3 ADULT
14.4 PEDIA
15 GLOBAL BRONCHIOLITIS DRUGS MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITAL
15.3 SPECIALTY CLINICS
15.4 AMBULATORY CENTERS
15.5 OTHERS
16 GLOBAL BRONCHIOLITIS DRUGS MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 HOSPITALS PHARMACY
16.4 RETAIL PHARMACY
16.5 ONLINE PHARMACY
16.6 OTHERS
17 GLOBAL BRONCHIOLITIS DRUGS MARKET, BY GEOGRAPHY
GLOBAL BRONCHIOLITIS DRUGS MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
17.1 NORTH AMERICA
17.1.1 U.S.
17.1.1.1. U.S. BRONCHIOLITIS DRUGS MARKET, BY TREATMENT TYPE
17.1.1.2. U.S. BRONCHIOLITIS DRUGS MARKET, BY SUB TYPE
17.1.1.3. U.S. BRONCHIOLITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION
17.1.1.4. U.S. BRONCHIOLITIS DRUGS MARKET, BY POPULATION TYPE
17.1.1.5. U.S. BRONCHIOLITIS DRUGS MARKET, BY END USER
17.1.1.6. U.S. BRONCHIOLITIS DRUGS MARKET, BY DISTRIBUTION CHANNEL
17.1.2 CANADA
17.1.3 MEXICO
17.1.4 DOMINICAN REPUBLIC
17.1.5 JAMAICA
17.1.6 PANAMA
17.2 EUROPE
17.2.1 GERMANY
17.2.2 FRANCE
17.2.3 U.K.
17.2.4 HUNGARY
17.2.5 LITHUANIA
17.2.6 AUSTRIA
17.2.7 IRELAND
17.2.8 NORWAY
17.2.9 POLAND
17.2.10 ITALY
17.2.11 SPAIN
17.2.12 RUSSIA
17.2.13 TURKEY
17.2.14 NETHERLANDS
17.2.15 SWITZERLAND
17.2.16 REST OF EUROPE
17.3 ASIA-PACIFIC
17.3.1 JAPAN
17.3.2 CHINA
17.3.3 TAIWAN
17.3.4 SOUTH KOREA
17.3.5 INDIA
17.3.6 AUSTRALIA
17.3.7 SINGAPORE
17.3.8 THAILAND
17.3.9 MALAYSIA
17.3.10 INDONESIA
17.3.11 PHILIPPINES
17.3.12 VIETNAM
17.3.13 REST OF ASIA-PACIFIC
17.4 SOUTH AMERICA
17.4.1 BRAZIL
17.4.2 ECUADOR
17.4.3 CHILE
17.4.4 COLOMBIA
17.4.5 VENEZUELA
17.4.6 ARGENTINA
17.4.7 PERU
17.4.8 CURAÇAO
17.4.9 PARAGUAY
17.4.10 URUGUAY
17.4.11 TRINIDAD AND TOBAGO
17.4.12 REST OF SOUTH AMERICA
17.5 MIDDLE EAST AND AFRICA
17.5.1 SOUTH AFRICA
17.5.2 SAUDI ARABIA
17.5.3 UAE
17.5.4 EGYPT
17.5.5 KUWAIT
17.5.6 ISRAEL
17.5.7 BOLIVIA
17.5.8 REST OF MIDDLE EAST AND AFRICA
17.5.9 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
18 GLOBAL BRONCHIOLITIS DRUGS MARKET, SWOT AND DBMR ANALYSIS
19 GLOBAL BRONCHIOLITIS DRUGS MARKET, COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: GLOBAL
19.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
19.3 COMPANY SHARE ANALYSIS: EUROPE
19.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
19.5 MERGERS & ACQUISITIONS
19.6 NEW PRODUCT DEVELOPMENT & APPROVALS
19.7 EXPANSIONS
19.8 REGULATORY CHANGES
19.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
20 GLOBAL BRONCHIOLITIS DRUGS MARKET, COMPANY PROFILE
20.1 NOVARTIS
20.1.1 COMPANY OVERVIEW
20.1.2 REVENUE ANALYSIS
20.1.3 GEOGRAPHIC PRESENCE
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPEMENTS
20.2 BOEHRINGER INGELHEIM
20.2.1 COMPANY OVERVIEW
20.2.2 REVENUE ANALYSIS
20.2.3 GEOGRAPHIC PRESENCE
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPEMENTS
20.3 DR REDDY’S LABORATORIES
20.3.1 COMPANY OVERVIEW
20.3.2 REVENUE ANALYSIS
20.3.3 GEOGRAPHIC PRESENCE
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPEMENTS
20.4 GLAXOSMITHKLINE PHARMACEUTICALS
20.4.1 COMPANY OVERVIEW
20.4.2 REVENUE ANALYSIS
20.4.3 GEOGRAPHIC PRESENCE
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPEMENTS
20.5 PFIZER
20.5.1 COMPANY OVERVIEW
20.5.2 REVENUE ANALYSIS
20.5.3 GEOGRAPHIC PRESENCE
20.5.4 PRODUCT PORTFOLIO
20.5.5 RECENT DEVELOPEMENTS
20.6 ABBVIE
20.6.1 COMPANY OVERVIEW
20.6.2 REVENUE ANALYSIS
20.6.3 GEOGRAPHIC PRESENCE
20.6.4 PRODUCT PORTFOLIO
20.6.5 RECENT DEVELOPEMENTS
20.7 MERCK & CO., INC
20.7.1 COMPANY OVERVIEW
20.7.2 REVENUE ANALYSIS
20.7.3 GEOGRAPHIC PRESENCE
20.7.4 PRODUCT PORTFOLIO
20.7.5 RECENT DEVELOPEMENTS
20.8 HIKMA PHARMACEUTICALS
20.8.1 COMPANY OVERVIEW
20.8.2 REVENUE ANALYSIS
20.8.3 GEOGRAPHIC PRESENCE
20.8.4 PRODUCT PORTFOLIO
20.8.5 RECENT DEVELOPEMENTS
20.9 GALEN PHARMA
20.9.1 COMPANY OVERVIEW
20.9.2 REVENUE ANALYSIS
20.9.3 GEOGRAPHIC PRESENCE
20.9.4 PRODUCT PORTFOLIO
20.9.5 RECENT DEVELOPEMENTS
20.1 BAYER HEALTHCARE
20.10.1 COMPANY OVERVIEW
20.10.2 REVENUE ANALYSIS
20.10.3 GEOGRAPHIC PRESENCE
20.10.4 PRODUCT PORTFOLIO
20.10.5 RECENT DEVELOPEMENTS
20.11 AMGEN
20.11.1 COMPANY OVERVIEW
20.11.2 REVENUE ANALYSIS
20.11.3 GEOGRAPHIC PRESENCE
20.11.4 PRODUCT PORTFOLIO
20.11.5 RECENT DEVELOPEMENTS
20.12 JOHNSON & JOHNSON
20.12.1 COMPANY OVERVIEW
20.12.2 REVENUE ANALYSIS
20.12.3 GEOGRAPHIC PRESENCE
20.12.4 PRODUCT PORTFOLIO
20.12.5 RECENT DEVELOPEMENTS
20.13 GENENTECH, INC.
20.13.1 COMPANY OVERVIEW
20.13.2 REVENUE ANALYSIS
20.13.3 GEOGRAPHIC PRESENCE
20.13.4 PRODUCT PORTFOLIO
20.13.5 RECENT DEVELOPEMENTS
20.14 F. HOFFMANN LA ROCHE
20.14.1 COMPANY OVERVIEW
20.14.2 REVENUE ANALYSIS
20.14.3 GEOGRAPHIC PRESENCE
20.14.4 PRODUCT PORTFOLIO
20.14.5 RECENT DEVELOPEMENTS
20.15 SANOFI
20.15.1 COMPANY OVERVIEW
20.15.2 REVENUE ANALYSIS
20.15.3 GEOGRAPHIC PRESENCE
20.15.4 PRODUCT PORTFOLIO
20.15.5 RECENT DEVELOPEMENTS
20.16 FRESENIUS KABI
20.16.1 COMPANY OVERVIEW
20.16.2 REVENUE ANALYSIS
20.16.3 GEOGRAPHIC PRESENCE
20.16.4 PRODUCT PORTFOLIO
20.16.5 RECENT DEVELOPMENTS
20.17 TEVA PHARMACEUTICALS
20.17.1 COMPANY OVERVIEW
20.17.2 REVENUE ANALYSIS
20.17.3 GEOGRAPHIC PRESENCE
20.17.4 PRODUCT PORTFOLIO
20.17.5 RECENT DEVELOPEMENTS
20.18 HOSPIRA PHARMACEUTICALS
20.18.1 COMPANY OVERVIEW
20.18.2 REVENUE ANALYSIS
20.18.3 GEOGRAPHIC PRESENCE
20.18.4 PRODUCT PORTFOLIO
20.18.5 RECENT DEVELOPEMENTS
20.19 TAKEDA PHARMACEUTICAL
20.19.1 COMPANY OVERVIEW
20.19.2 REVENUE ANALYSIS
20.19.3 GEOGRAPHIC PRESENCE
20.19.4 PRODUCT PORTFOLIO
20.19.5 RECENT DEVELOPEMENTS
20.2 SUN PHARMA
20.20.1 COMPANY OVERVIEW
20.20.2 REVENUE ANALYSIS
20.20.3 GEOGRAPHIC PRESENCE
20.20.4 PRODUCT PORTFOLIO
20.20.5 RECENT DEVELOPEMENTS
20.21 CIPLA
20.21.1 COMPANY OVERVIEW
20.21.2 REVENUE ANALYSIS
20.21.3 GEOGRAPHIC PRESENCE
20.21.4 PRODUCT PORTFOLIO
20.21.5 RECENT DEVELOPEMENTS
20.22 ASTRAZENECA
20.22.1 COMPANY OVERVIEW
20.22.2 REVENUE ANALYSIS
20.22.3 GEOGRAPHIC PRESENCE
20.22.4 PRODUCT PORTFOLIO
20.22.5 RECENT DEVELOPEMENTS
*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
21 RELATED REPORTS
22 CONCLUSION
23 QUESTIONNAIRE
